Introduction {#s1}
============

Erdheim-Chester disease (ECD) is a rare multisystem non-Langerhans cell histiocytosis characterized by systemic xanthogranulomatous infiltration from histiocytes \[[@R01], [@R02]\]. This disease was first described by Erdheim and Chester in 1930 \[[@R03]\]. The number of cases reporting this disease is small (less than 600), but it has had dramatically increased in recent years, maybe by the increased diagnostic methods available, which enhances the recognition of the disease \[[@R04]\]. Patients with ECD commonly present in the fifth decade; however, pediatric and geriatric presentations have also been reported. ECD results from xanthogranulomatous infiltration of foamy histiocytes; these cells are positive for CD68, negative for CD1a, and in 80% of the cases negative for S100 \[[@R05]\]. ECD manifests as long bone infiltrations, exophthalmos, diabetes insipidus, xanthelasma, interstitial lung disease, bilateral adrenal infiltration, retroperitoneal fibrosis with perirenal or ureteral infiltration causing hydronephrosis and renal failure, testicular infiltration, and in exceptional involves the hearth and the central nervous system \[[@R06]\].

The diagnosis of ECD is based on radiologic and histologic criteria. Imaging studies are prompted for the bone pain referred by the patients. X-rays show bilateral symmetric metaphyseal osteosclerosis of long bones. These lesions are considered virtually pathognomonic. The 99mTc Bone Scintigraphy shows symmetric and abnormally strong 99mTc labeling of the distal ends of the long bones. Microscopy of the lesions shows typical ECD histiocytes. These histiocytes are non-Langerhans' foamy histiocytes, which lack Birbeck granules, nested within a polymorphic granuloma, fibrosis or xanthogranulomatous. Pathological confirmation of CD68^+^, CD1a^-^ histiocytes is both sufficient and mandatory for the diagnosis of ECD \[[@R06]\].

Specific somatic genetic mutations in the BRAF V600 gene have been reported in around 54% of patients suffering of ECD, rendering a therapeutic target for the kinase inhibitor, vemurafenib \[[@R07]\]. This medication is the only active Food and Drug Administration (FDA) approved treatment for ECD and has demonstrated long-term efficacy in patients with this genetic mutation \[[@R08]\]. Other medications, as dabrafenib (a BRAF V600E inhibitor) and trametinib (a mitogen-activated protein kinase inhibitor), are under study as potential therapeutic options \[[@R9]\].

Case Report {#s2}
===========

We present the case of a 53-year-old woman with diabetes insipidus that has been treated with desmopressin for about 8 years, migraine with aura, and known ECD confirmed by biopsy, with possible involvement of the great cardiac vessel and infiltrative cardiomyopathy. Over the past several years, she has dealt with a multitude of intermittently exacerbated symptoms, including headaches, fatigue, lethargy, exertional dyspnea, flushing, and peripheral edema, which have been clinically attributed to mast cell activation. She was admitted twice during the previous year with symptoms of fluid retention that resolved with diuresis. She was diagnosed with ECD 2 months before this admission, with biopsy confirmation from the vertebra and the left femur. She was admitted to our institution for further management of a newly identified large pericardial effusion ([Fig. 1](#F1){ref-type="fig"}) and ascites, accurately to assess the extension of the cardiac involvement by this disease. In the interim, she had complained of intermittent midsternal chest discomfort associated with dry cough and palpitations that worsened while lying flat.

![Large pericardial effusion.](cr-11-118-g001){#F1}

She was found to have an acute right frontal infarct and multifocal stenosis through the vessel imaging modalities. A magnetic resonance imaging (MRI) showed infarction in the right frontal and parietal white matter, while the magnetic resonance angiography (MRA) revealed extensive intracranial stenosis in the anterior circulation. The final cerebral angiogram showed a right internal carotid artery occlusion, likely secondary to fibromuscular dysplasia changes ([Fig. 2](#F2){ref-type="fig"}). Cerebrospinal fluid tests were normal, and the neurology service concluded that these changes were consistent with vasculopathy secondary to ECD with BRAF mutation.

![Right internal carotid artery occlusion.](cr-11-118-g002){#F2}

Transesophageal echocardiography (TEE) showed a large circumferential pericardial effusion greater than 2 cm with maximum thickness around the inferior and posterior left ventricle wall with the partial systolic collapse of the right atrium. She had an ejection fraction of 69% and large pericardial effusion without tamponade physiology. After the evacuation of the pericardial effusion via video-assisted thoracoscopic surgery (VATS), there was minimal pericardial effusion remaining. The pathology exam from pericardium showed histiocytic infiltration compatible with ECD, positive for the BRAF mutation. From these findings, it was concluded that the patient was suffering from a vasculopathy related to ECD. She received corticosteroids for the treatment of the histiocytosis caused by ECD.

She continued her desmopressin for her diabetes insipidus, and she was started on daily aspirin and prednisone, along with pantoprazole and vitamin D for stomach and bone protection. A limited echocardiogram 8 days after VATS showed significant improvement in pericardial effusion ([Fig. 3](#F3){ref-type="fig"}). She was discharged on colchicine, bumetanide and bactrim for prophylaxis against Pneumocystis jiroveci pneumonia. Before going home, a cardiac MRI was done to record the extension of the disease and help with future monitoring ([Fig. 4](#F4){ref-type="fig"}). It was planned to start vemurafenib due to the discovery of the BRAF mutation.

![Reduction in pericardial effusion compared to [Figure 1](#F1){ref-type="fig"}.](cr-11-118-g003){#F3}

![Cardiac MRI with very scarce effusion. MRI: magnetic resonance imaging.](cr-11-118-g004){#F4}

Methods {#s3}
=======

The process developed for the literature review included the following steps.

First, the relevant keywords were established. We conducted a broad search using the terms pericardial effusion and ECD.

Second, Scopus, PubMed, EMBASE, and Cochrane were searched for published articles through September 2019. The combinations of the terms used were: 1) SCOPUS, TITLE-ABS-KEY ("Erdheim-Chester Disease") AND TITLE-ABS-KEY ("Pericardial Effusion"); 2) PUBMED, "Erdheim-Chester Disease" (Mesh) AND "Pericardial Effusion" (Mesh); 3) EMBASE, TITLE-ABS-KEY ("Erdheim-Chester Disease") AND TITLE-ABS-KEY ("Pericardial Effusion"); and 4) COCHRANE, "Erdheim-Chester Disease" in Title Abstract Keyword AND "Pericardial Effusion" in Title Abstract Keyword (word variations have been searched). A total of 206 articles were found (84 from Scopus, 15 from PubMed, 107 from EMBASE and no articles found in Cochrane).

Third, article abstracts were reviewed for study eligibility, followed by reviews of full papers in cases in which eligibility was not clear from the abstract review alone. Another 18 full-text articles were excluded. [Figure 5](#F5){ref-type="fig"} shows the flow diagram according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@R07]\].

![Flow diagram according to the PRISMA statement. PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](cr-11-118-g005){#F5}

Selection of studies {#s3a}
--------------------

Articles were included if they consisted of presentation of pericardial effusion and ECD. Articles were excluded if they were primarily editorials, and solely described study protocols, letters, abstract of congresses or books. The results were summarized in tables.

Results {#s4}
=======

Fifty-two articles were included in the analysis. [Table 1](#T1){ref-type="table"} shows the main characteristics of them. Most of the studies were case reports, eight were reviews and only three were original articles. [Table 2](#T2){ref-type="table"} shows the case reports and case series in which patients with ECD presented with pericardial effusion \[[@R10]-[@R41]\]. The average age of the patients with ECD who presented with pericardial effusion was 56.64 ± 10.5. The majority of them were men (54.29%). [Table 3](#T3){ref-type="table"} shows the interventions in patients reviewed. Almost 40% of the patients reviewed did not need any cardiologic procedure. A total of 30.3% of the patients received pericardiocentesis. Four received pleuro-pericardial window; three, pericardial window and two, pericardiectomy. The following procedures were performed in only one patient: mediastinoscopy, pericardial drainage, and sternotomy. One patient had pericardiocentesis and later received pericardiectomy, and another had pericardiocentesis done twice and later a pleuro-cardial window.

###### Characteristics of Articles

  Characteristic               N    \%
  ---------------------------- ---- --------
  Type of article                   
    Case report                28   53.85%
    Review                     8    15.38%
    Letter                     4    7.69%
    Series of cases            4    7.69%
    Original                   3    5.77%
    Other small publications   5    9.62%
  Year                              
    2001                       1    1.92%
    2003                       1    1.92%
    2004                       1    1.92%
    2006                       2    3.85%
    2007                       1    1.92%
    2010                       3    5.77%
    2011                       3    5.77%
    2012                       3    5.77%
    2013                       2    3.85%
    2014                       5    9.62%
    2015                       6    11.54%
    2016                       8    15.38%
    2017                       6    11.54%
    2018                       8    15.38%
    2019                       2    3.85%

###### Reports That Present Cases of Erdheim-Chester Disease With Pericardial Effusion

  *Author*                      Y      S    A                   First manifestation                                                                                       TSD                    CV manifestations                                                                                    CP                                                                    Treatment                                                                           O           TO
  ----------------------------- ------ ---- ------------------- --------------------------------------------------------------------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------- -----------
  *Andre*\[[@R12]\]             2001   M    57                  Exophthalmos                                                                                              UK                     Pericarditis and cardiac tamponade                                                                   Mediastinoscopy                                                       Prednisone, diuretics ACE                                                           UK          UK
  *Curgunlu*\[[@R13]\]          2003   M    43                  Swelling and pain in his right knee                                                                       10 months              Moderate pericardial effusion                                                                        \-                                                                    Prednisolone, palliative therapy for pain                                           Stable      6 months
  *Johnson*\[[@R14]\]           2004   M    34                  Migraines, headache                                                                                       3 years                Pericardial effusion                                                                                 Pericardial drainage                                                                                                                                      UK          UK
  *Palotas*\[[@R15]\]           2006   M    57                  Already diagnosed at the presentation                                                                     UK                     Pericardial effusion with left ventricle enlarged                                                    \-                                                                    UK                                                                                  UK          
  *Saboerali*\[[@R16]\]         2006   M    45                  Chest pain and a nonproductive cough                                                                      2.5 years              Pericardial thickening and effusions without inflow disruption                                       \-                                                                    UK                                                                                  UK          UK
  *Palotas*\[[@R17]\]           2007   M    57                  Pericardial effusion and exophthalmos                                                                     UK                     Pericardial effusion                                                                                 Sternotomy                                                            UK                                                                                  UK          UK
  *Alharthi*\[[@R10]\]          2010   F    53                  Bilateral ankle swelling and shortness of breath                                                          1 year                 Large pericardial effusion and pan cardiac involvement                                               Pericardiocentesis                                                    Cladribine                                                                          Stable      12 months
  *Kim*\[[@R18]\]               2010   M    68                  Multiple yellowish plaques and a pinkish nodule on his face and scalp                                     1.5 years              Moderate pericardial effusion                                                                        \-                                                                    Interferon-α                                                                        Stable      16 months
  *Lutz*\[[@R19]\]              2011   F    65                  Recurrent pericardial effusion                                                                            3 months               Chronic pericardial effusion, a mass attached to the pericardium, and a thickened aorta              Pericardiocentesis                                                    Glucocorticoids and interferon-α                                                    Dead        UK
  *Vega*\[[@R20]\]              2011   M    76                  Progressive congestive heart failure                                                                      8 months               Pericarditis and cardiac tamponade                                                                   Pleuro-pericardial window                                             Steroids and methotrexate                                                           UK          UK
  *Egan*\[[@R21]\]              2011   F    53                  Progressive dyspnea on exertion and lower extremity edema                                                 1 year                 Mild chronic fibrosing pericarditis and pericardial effusion                                         Pleuro-pericardial window                                             UK                                                                                  Stable      4 months
  *Ota*\[[@R22]\]               2012   F    77                  Dyspnea on exertion                                                                                       1 year                 Pericardial effusion                                                                                 Pericardiocentesis                                                    Methylprednisolone and then interferon-α                                            UK          UK
  *Takeuchi*\[[@R23]\]          2012   M    56                  Left exophtalmus                                                                                          UK                     Pericardial effusion                                                                                 \-                                                                    UK                                                                                  UK          
  *Dagna*\[[@R24]\]             2012   M    56                  Recurrent pericardial effusion, recent cardiac tamponade and signs of heart failure                       2 years                Recurrent pericardial effusion, recent cardiac tamponade and signs of heart failure                  Pericardial window                                                    Infliximab and methotrexate                                                         Stable      30 months
                                M      60   Already diagnosed   UK                                                                                                        Pericardial effusion   \-                                                                                                   Infliximab and methotrexate                                           Stable                                                                              12 months   
  *Dogan*\[[@R25]\]             2013   M    62                  Recurrent pericardial effusion                                                                            5 months               Large amount of pericardial effusion, and a mass which surrounds the right atrium                    Pericardiocentesis + pericardiocentesis + pleuro-pericardial window   Methylprednisolone and cyclophosphamide                                             Stable      UK
  *Alexiou*\[[@R26]\]           2015   F    56                  Mesenteric panniculitis                                                                                   8 years                Recurrent pericardial effusion                                                                       \-                                                                    UK                                                                                  Dead        
  *De Miguel*\[[@R27]\]         2015   F    61                  Symptoms of congestive heart failure                                                                      1 week                 Irregular right atrial mass and moderate to severe pericardial effusion                              \-                                                                    Corticosteroids                                                                     Stable      12 months
  *Mishra*\[[@R28]\]            2015   M    57                  Worsening dyspnea, non-productive cough, reduced appetite and weight loss                                 6 months               Recurrent large pericardial effusion, pericardial thickening and right ventricular collapse          Pericardiocentesis                                                    Glucocorticoids and interferon-α                                                    Dead        
  *Abdellateef*\[[@R29]\]       2016   F    19                  Unilateral left exophthalmos                                                                              6 years                Cardiac tamponade                                                                                    Pericardiocentesis                                                    Prednisolone and azathioprine                                                       Stable      1 month
  *Azadeh*\[[@R30]\]            2016   M    61                  Pleural and cardiac effusion                                                                              4 months               Cardiac muscle hypertrophy, pericardial effusion and adhesions                                       \-                                                                    Cladribine                                                                          Improved    6 months
  *Mathis*\[[@R31]\]            2016   F    59                  Chronic headaches and asthenia                                                                            5 years                Right peri-atrial infiltration, thickening of the wall of the aortic arch and pericardial effusion   \-                                                                    Interferon-α and clopidogrel                                                        Stable      4 years
  *Nakhleh*\[[@R32]\]           2016   M    68                  Weight loss and general weakness                                                                          6 months               Cardiomegaly and small pericardial effusion                                                          Pericardiocentesis                                                    Interferon-α                                                                        Dead        
  *Peric*\[[@R33]\]             2016   M    23                  Severe exophthalmos and vision loss of the left eye                                                       6 months               Pericardial thickening with effusion and right atrial collapse                                       \-                                                                    Cladribine                                                                          Improved    12 years
  *Kyriakopoulou*\[[@R34]\]     2016   F    77                  Bilateral exophthalmos, orbital xanthogranuloma and fatigue                                               4 months               Acute cardiac tamponade                                                                              Pericardiocentesis                                                    Corticosteroids + subcutaneous interferon-α-2b then changed to peginterferon-α-2a   Stable      12 months
  *Bentel*\[[@R35]\]            2017   M    54                  Left adrenal mass                                                                                         UK                     Pericardial effusion                                                                                 Pericardial window                                                    No specific treatment                                                               Stable      8 years
  *Chasseur*\[[@R36]\]          2017   F    74                  Giant xanthelasma and progressive bilateral exophthalmos causing partial loss of vision                   3 months               Massive cardiac tamponade with right ventricular compression                                         Pericardiocentesis                                                    Corticosteroids and then interferon-α                                               Improved    4 months
  *Franco-Palacios*\[[@R37]\]   2017   M    20                  Subacute non-productive cough, new onset orthopnea and exertional dyspnea at rest                         1 month                Pericardial effusion                                                                                 Pericardial window                                                    Steroids and interferon-α                                                           Improved    13 months
  *Zhu*\[[@R38]\]               2017   F    51                  Shortness of breath, chest pain, recurrent edema of legs and night sweats                                 UK                     Pericardial effusion                                                                                 Pericardiectomy                                                       Interferon-α                                                                        Stable      7 months
  *Liersch^a^*\[[@R39]\]        2017   F    75                  Ulcerating sub mammary plaques, yellowish rash on central trunk and keratotic plaques on her lower legs   13 years               Small pericardial effusions                                                                          \-                                                                    Interferon-α and local PUVA then methotrexate                                       Stable      12 months
  *Monmany*\[[@R40]\]           2018   F    69                  Exophthalmos and facial pain                                                                              6 months               Heterogeneous mass and pericardial effusion                                                          Pericardiocentesis + pericardiectomy                                  Pegylated interferon-α-2a                                                           Improved    3 months
  *Tomelleri*\[[@R41]\]         2018   M    62                  Recurrent pericardial effusions                                                                           1 year                 Recurrent pericardial effusions                                                                      Pleuro-pericardial window                                             Anakinra                                                                            Improved    2 months
  *Costa^a^*\[[@R11]\]          2018   F    64                  Already diagnosed at the presentation                                                                     UK                     Atrial pseudotumor, pericardial thickening and effusion                                              \-                                                                    UK                                                                                  UK          

Y: year; S: sex; A: age; TSD: time from start of symptoms to diagnosis; TO: time to outcome; CV: cardiovascular; UK: unknown; CP: cardiovascular procedure; ACE: angiotensin-converting enzyme; PUVA: photochemotherapy.^a^Only one of the cases presented with pleural effusion.

###### Interventions Performed in the Cases of Erdheim-Chester Disease With Pericardial Effusion

  Procedure                                                             N    \%
  --------------------------------------------------------------------- ---- --------
  None                                                                  13   39.39%
  Pericardiocentesis                                                    8    24.24%
  Pericardial window                                                    3    9.09%
  Pleuro-pericardial window                                             3    9.09%
  Mediastinoscopy                                                       1    3.03%
  Pericardectomy                                                        1    3.03%
  Pericardial drainage                                                  1    3.03%
  Sternotomy                                                            1    3.03%
  Pericardiocentesis + pericardectomy                                   1    3.03%
  Pericardiocentesis + pericardiocentesis + pleuro-pericardial window   1    3.03%

Discussion {#s5}
==========

Approximately 75% of patients with ECD suffer cardiovascular manifestations and about 60% of them will perish due to cardiac complications \[[@R10]\]. Patients with ECD and cardiac involvement have a reduced response to treatment and a poor overall prognosis \[[@R42]\]. There are several types of cardiac injuries that can cause congestive heart failure, including myocardial infarction, thromboembolism, cardiac remodeling, valve dysfunction, ischemia, and peripheral edema among others. Pericardial infiltration is the most frequent cardiac manifestation of ECD \[[@R43]\] and is the one discussed in this article.

Pericardial involvement in ECD takes several forms and the symptoms are correlated with type, extent, and severity. Pericardial infiltration is easily discovered with computed tomography and transthoracic echocardiography. The pericardium may appear thickened with or without a fibrosis wrap. The accumulation of pericardial effusion can lead to cardiac tamponade. This can be relieved with pericardiocentesis, which has diagnostic and therapeutic purposes. Aggressive interventions may include placement of a pericardial window, pericardiectomy, and placement of a pericardial-abdominal shunt. Cytological examination of pericardial effusion can reveal mesothelial cells, histiocytes, and inflammatory cells. A histological examination of a pericardial sample may reveal the infiltration of foamy histiocytes \[[@R44]\]. In our revision, we found that the majority of the patients with pericardial infiltration needed a cardiovascular procedure. Pericardial infiltration can manifest as pericardial thickening and symptoms vary according to the degree of disease severity. Myocardial involvement occurs sequentially to the pericardial involvement and manifests as myocardial hypertrophy, easily diagnosed by the echocardiogram. Thickening can be found in the ventricles, atria, coronary sulci and interatrial septum \[[@R11]\].

To date, several treatments have been administered to patients with ECD in an attempt to achieve remission or at least stabilization. Currently, interferon-α provides the best management strategy, with a sustainable stabilization of the disease in most cases \[[@R45]-[@R48]\]. Interferon-α is administered in doses that vary from three million units three times per week to nine million units three times per week. Peginterferon-α-2a, the pegylated form of interferon-α, is an equivalent alternative to interferon-α. It is administered in doses that vary from 135 to 200 µg per week \[[@R45]\]. It should be noted that treatment with these agents is prolonged. Therefore, treatment tolerance should be considered fundamental in long-term treatment planning. Among the adverse effects of interferon-α are asthenia, myalgia, pruritus, thrombocytopenia, and depression \[[@R49]\].

The efficacy of interferon-α varies according to the different sites of disease involvement. A recent survey involving 24 patients treated with high doses of interferon-α (\> 18 million units per week) or high doses of peginterferon-α-2a (\> 185 µg per week) reported that they were effective in treating patients with severe ECD. The response to treatment was most prominent in the cutaneous foci of the disease, followed by foci in the central nervous system (CNS) and pituitary; foci of the lung and heart were more resistant to treatment \[[@R49]\]. Interferon-α treatment itself was identified as an independent predictor of survival. It is currently the only agent that has been shown to improve survival among patients with ECD. Cladribine is recommended as an alternative treatment for ECD. However, the literature contains significantly fewer data regarding this medication compared to interferon-α \[[@R45]\].

In the past, vemurafenib proved to be an effective therapeutic option in patients with melanoma-BRAF V600 mutation; the reason why this medication was tested in patients with ECD was a link found between this disease and a specific BRAF V600 mutation. A nonrandomized, open-label phase 2 clinical trial by Diamond et al showed long-term efficacy in patients with BRAF V600-mutant ECD \[[@R08]\]. Vemurafenib gained FDA approval in 2017 with an oral dose of 960 mg every 12 h. Common side effects include arthralgia, alopecia, maculopapular rash, fatigue, photosensitivity, uveitis, and prolonged QT interval. Skin cancer, anaphylaxis, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatotoxicity, kidney failure, Dupuytren's contracture and teratogenicity have been described as rare but severe side effects.

Conclusions {#s5a}
-----------

ECD is a rare non-Langerhans cell histiocytosis characterized by systemic xanthogranulomatous infiltration. We described the case of a female adult presenting with pericardial effusion. Pericardial infiltration is the most frequent cardiac manifestation of ECD and is the one discussed in this article. We found that the majority of the patients with pericardial infiltration needed a cardiovascular procedure.
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